Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of
somatotropinomas, thyrotropinomas, and functioning and non-functioning …

M. Pavel a D. O'Toole b F. Costa c J. Capdevila d D. Gross e R. Kianmanesh f E. Krenning g
U. Knigge h R. Salazar i U.-F. Pape a K. Öberg j all other Vienna Consensus Conference …

Carcinoid heart disease is a frequent occurrence in patients with carcinoid syndrome and is
responsible for substantial morbidity and mortality. The pathophysiology of carcinoid heart …

In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release
(pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing …

Pancreatic neuroendocrine tumors (PNETs), a group of endocrine tumors arising in the
pancreas, are among the most common neuroendocrine tumors. The genetic causes of …

There have been numerous advances in all aspects of the carcinoid-syndrome, which is the
most common functional syndrome neuroendocrine tumors produce. These advances are …

The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …